Shares of Replimune Group, Inc. (REPL) have gained 2.7% over the past four weeks to close the last trading session at $7.16, but there could still be a solid upside left in the stock if short-term ...

BAYRY wins preliminary court approval for a proposed Roundup class settlement, a key step in managing long-running glyphosate litigation and future liabilities.

Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members from the Replimune management t ...

Esperion Therapeutics ESPR announced that it has entered into a definitive agreement to acquire Nevada-based, privately held, commercial-stage biopharmaceutical company, Corstasis Therapeutics, for ...

The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology ...

The biotech industry has broadly been on the upswing, with the SPDR S&P Biotech ETF up 43% in the past 12 months, but many rare disease names are facing a measurably higher bar from investors. There’s ...

Who were the biggest winners on Day 1 of the 2026 NFL Scouting Combine workouts? Did Penn State DT Zane Durant show today ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Hit the ground running with Morningstar’s flagship product, built specifically for the way you work.